Meta-analysis finds bright light therapy boosts remission and response in nonseasonal depression, offering a low-cost add-on to standard care.
|Slideshows|August 7, 2020
5 Fast Facts for Addressing Distress & Depression in Cancer
Despite advances in clinical care for patients with cancer, distress and depression continue to haunt patients. These fast facts will help you better understand and care for patients with cancer.
Advertisement
Advertisement
Related to this article
Mixed-feature depression can signal bipolar risk; spot red flags and consider lurasidone or lumateperone before standard antidepressants.
Compass Pathways has completed its submission of an NDA to the FDA for COMP360 psilocybin for treatment-resistant depression.
GLP-1 drugs enter psychiatry, curbing antipsychotic weight gain while raising new questions about addiction, mood, eating disorders, and culture.
Alkermes launches a phase 2 trial of oral orexin-2 agonist ALKS 7290 to boost antidepressant response in major depressive disorder, assessing safety and symptom relief.
Advertisement
Advertisement
Trending on Psychiatric Times
1
Major Depressive Disorder With Mixed Features: Diagnosis and Treatment
2
FDA Shelves Fast-Track Drug Review Initiative
3
New National Guidance for Managing Medetomidine Intoxication and Withdrawal
4
Ahead of the FDA Action Date: A Timeline of Igalmi for Agitation in Bipolar Disorder and Schizophrenia
5